CSSSI

(redirected from Complicated Skin and Skin Structure Infections)
AcronymDefinition
CSSSIComplicated Skin and Skin Structure Infections
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
* The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI)
The FDA granted ceftobiprole fast-track designation for the treatment of complicated skin and skin structure infections due to methicillin-resistant Staphylococcus species and for a second indication in the treatment of hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
"Ceftaroline monotherapy was as effective and well tolerated as vancomycin plus aztreonam combination therapy in treating patients with complicated skin and skin structure infections due to both gram-positive and gram-negative pathogens," reported Dr.
The proposed indication for telavancin is for the treatment of complicated skin and skin structure infections (cSSSI) caused by Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus anginosus group, and Enterococcus faecalis.
A lower dose was approved in 2003 for complicated skin and skin structure infections caused by susceptible isolates of several gram-positive organisms.
CHICAGO -- Help is on the way for treatment of patients with complicated skin and skin structure infections.
Dalbavancin could be an alternative to vancomycin and linezolid for complicated skin and skin structure infections caused by gram-positive pathogens, and since it can be administered in outpatient settings, it might be a reasonable option for empirical treatment of such infections suspected to be caused by MRSA, the investigators said.
Approval was based on studies in more than 1,400 adults showing that Cubicin was equal to standard treatments, such as vancomycin, or a semisynthetic penicillin such as oxacillin or nafcillin, in treating complicated skin and skin structure infections, the FDA said in a statement.
The Food and Drug Administration has expanded the indications for Levaquin to include complicated skin and skin structure infections, such as major abscesses; ulcers; and infections of deep.wounds due to surgical incisions, bites, or lacerations.
The antibiotic was also approved for hospital-acquired pneumonia (HAP) and complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), as well as community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections.